Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 21:59:44
Portage Biotech Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
0,5134 2,27 0,01 215 148
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.02.2026
Popis společnosti
Obecné informace
Název společnostiAlphaTON Capital Corp
TickerATON
Kmenové akcie:Ordinary Shares
RICATON.O
ISIN-
Poslední známé roční výsledky31.03.2025
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.03.2025 3
Akcie v oběhu k 25.11.2025 7 626 488
MěnaUSD
Kontaktní informace
UliceClarence Thomas Building, Road Town
MěstoTORTOLA
PSČVG1110
ZeměVirgin Islands (British)
Kontatní osobaAndrew Hudders
Funkce kontaktní osobyInvestor Relations
Telefon14 169 291 806
Fax14169296612
Kontatní telefon12 129 077 349

Business Summary: AlphaTON Capital Corp., formerly Portage Biotech Inc., is a specialized digital asset treasury company. The Company is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The Company implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. It is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The Company engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2025, AlphaTON Capital Corp revenues was not reported. Net loss decreased 91% to $6.8M. Lower net loss reflects Material segment loss decrease of 59% to $7.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$77.90 to -$5.72.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Blockchain & Cryptocurrency (NEC)
RBSS2004Oil & Gas Exploration & Production
MGINDUSTRYInvestment Services
MGSECTORFinancial
NAICSCommodity Contracts Intermediation
NAICSMiscellaneous Financial Investment Activities
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCrude Petroleum And Natural Gas
SICCommodity Contracts Brokers/dlrs
SICSecurity/commodity Services Nec
SICCommercial Physical Research



  • Poslední aktualizace: 15.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardIan Walters-15.12.202401.05.2019
Chief Executive Officer, DirectorAlexander Pickett-15.12.202415.12.2024
Chief Financial OfficerAndrea Park-30.09.202430.09.2024
Chief Scientific OfficerRobert Kramer-08.01.201908.01.2019
Vice President - DevelopmentJustin Fairchild-18.08.202218.08.2022
Chief Business OfficerBrian Wiley5115.02.202215.02.2022